Comment from Huntington's Disease Society of America

Summary: The Huntington’s Disease Society of America (HDSA) supports the proposed framework for rare disease drug development outlined in the Haystack Project petition. They argue that the FDA should adopt disease-specific context, innovative trial designs, and formal consultations with experts to address the challenges of treating small, heterogeneous patient populations.